• Revenue up 60% to $5.2 million
• Loss after tax up 86% to $1.0 million
• Strong growth in clinical trial services revenue

Resonance Health Limited, a developer of software-as-medical-device (SaMD) technologies, has reported its financial results for the first half of the 2024 financial year. The company's revenue increased by 60% to $5.2 million, driven by continued growth in sales of its core SaMD products, including FerriScan, FerriSmart, and HepaFatSmart, as well as a significant contribution from its clinical trial services business. The company's loss after tax increased by 86% to $1.0 million, which included an income tax benefit of $473,286 from the group's R&D tax incentive. The higher loss was primarily due to increased expenses related to the expansion of the company's clinical trial services business, including the acquisition of TrialsWest Pty Ltd. Resonance Health's intangible assets, including capitalized R&D, goodwill, and other intangibles, totaled $9.7 million at the end of the half-year. The company ended the period with $3.5 million in cash and cash equivalents.

The company did not provide any specific forward-looking financial guidance in the announcement.

The company did not provide any detailed forward-looking outlook in the announcement, but stated that it continues to focus on the development and commercialization of its SaMD technologies and the expansion of its clinical trial services business.